Gotistobart Biosimilar - Research Grade

Human

CTLA4

>1mg/ml

IgG1 - kappa

CHO Cells

Ipilimumab Biosimilar - Research Grade (ICH4025), Tremelimumab Biosimilar - Research Grade (ICH5184), Botensilimab Biosimilar - Research Grade (ICH5412), Evalstotug Biosimilar - Research Grade (ICH5538), Firastotug Biosimilar - Research Grade (ICH5550), Muzastotug Biosimilar - Research Grade (ICH5696), Nurulimab Biosimilar - Research Grade (ICH5717), Quavonlimab Biosimilar - Research Grade (ICH5794), Sovipostobart Biosimilar - Research Grade (ICH5879), Tazlestobart Biosimilar - Research Grade (ICH5904), Tuvonralimab Biosimilar - Research Grade (ICH5951), Vilastobart Biosimilar - Research Grade (ICH5979), Zalifrelimab Biosimilar - Research Grade (ICH5998)

https://www.imgt.org/mAb-DB/

ICH3002

P16410

Blue ice

This is a research-grade biosimilar of gotistobart, supplied as an unconjugated, non-therapeutic recombinant analog of the originator anti-CTLA-4 antibody, built around the human CTLA-4 (CD152) target. It is a human IgG1-kappa molecule intended strictly for research use only (RUO); it is not the clinical drug and is not for human or veterinary use. The format is well suited to in-vitro and preclinical research applications such as CTLA-4 binding and blockade assays, competition and epitope-mapping studies, ADCC/effector-function characterization, flow-cytometry staining of CTLA-4-expressing cells, immunoassay standards, and as a positive or isotype-matched reference control in checkpoint-inhibitor workflows. It is also useful as a benchmarking reagent when developing or validating novel anti-CTLA-4 candidates. The product is manufactured to low-endotoxin specifications (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and is available in bulk milligram-to-gram quantities for scale-dependent screening, assay development, and preclinical model work. Because it targets human CTLA-4, its primary value is in human-cell and human-antigen systems rather than as a therapeutic. CTLA-4 (cytotoxic T-lymphocyte-associated protein 4; CD152; UniProt P16410) is an inhibitory immune-checkpoint receptor expressed on activated conventional T cells and constitutively on regulatory T cells (Tregs). It is a member of the immunoglobulin superfamily and shares the ligands CD80 (B7-1) and CD86 (B7-2) with the co-stimulatory receptor CD28, but binds them with substantially higher affinity and avidity. By outcompeting CD28 for these B7 ligands, and by physically removing them from antigen-presenting cells through trans-endocytosis, CTLA-4 dampens the co-stimulatory signals required for full T-cell activation. This delivers a critical negative regulatory brake on early T-cell responses and is central to peripheral immune tolerance. Because CTLA-4 blockade can enhance T-cell activation and antitumor immunity, it is a key target in cancer immunotherapy research and in studies of autoimmunity and Treg biology.

Cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4, CD152

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks